Critical appraisal of the role of pegloticase in the management of gout

References

• WuXWLeeCCMuznyDMCaskeyCTUrate oxidase: primary structure and evolutionary implicationsProc Natl Acad Sci U S A198986941294162594778
   PubMed Web of Science ®Google Scholar
• ZhangWDohertyMBardinTEULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)Ann Rheum Dis2006651312132416707532
   PubMed Web of Science ®Google Scholar
• StampLKO’DonnellJLZhangMUsing allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairmentArthritis Rheum20116341242121279998
   PubMed Web of Science ®Google Scholar
• KeithMPGillilandWRImproving the use of allopurinol in chronic gout: monitoring oxypurinol levels to guide therapyClin Pharmacol Ther20119036336421862966
   PubMed Web of Science ®Google Scholar
• StampLKBarclayMLO’DonnellJLRelationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate levelClin Pharmacol Ther20119039239821796116
   PubMed Web of Science ®Google Scholar
• SarawateCABrewerKKYangWGout medication treatment patterns and adherence to standards of care from a managed care perspectiveMayo Clin Proc20068192593416835972
   PubMed Web of Science ®Google Scholar
• GarayRPEl-GewelyMRLabauneJPRichettePTherapeutic perspectives on uricases for goutJoint Bone Spine201279323724222366146
   PubMed Web of Science ®Google Scholar
• US Food and Drug AdministrationPegloticase: full prescribing information2010 Available from: http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=41481Accessed October 17, 2011
   Google Scholar
• RamazzinaIFolliCSecchiABerniRPercudaniRCompleting the uric acid degradation pathway through phylogenetic comparison of whole genomesNat Chem Biol2006214414816462750
   PubMed Web of Science ®Google Scholar
• TiptonPAUrate to allantoin, specifically (S)-allantoinNat Chem Biol2006212412516485000
   PubMed Web of Science ®Google Scholar
• RichettePBriereCHoenen-ClavertVLoeuilleDBardinTRasburicase for tophaceous gout not treatable with allopurinol: an exploratory studyJ Rheumatol2007342093209817896799
   PubMed Web of Science ®Google Scholar
• ShermanMRWilliamsLDSobczykMAMichaelsSJSaiferMGRole of the methoxy group in immune responses to mPEG-protein conjugatesBioconjug Chem20122348549922332808
   PubMed Web of Science ®Google Scholar
• SundyJSBeckerMABarafHSReduction of plasma urate levels following treatment with multiple doses of pegloticase (polyethylene glycol-conjugated uricase) in patients with treatment-failure gout: results of a phase II randomized studyArthritis Rheum2008582882289118759308
   PubMed Web of Science ®Google Scholar
• SundyJSBarafHSBYoodRAEfficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trialsJAMA201130671172021846852
   PubMed Web of Science ®Google Scholar
• SundyJSGansonNJKellySJPharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory goutArthritis Rheum2007561021102817328081
   PubMed Web of Science ®Google Scholar
• YueCSHuangWAltonMPopulation pharmacokinetic and pharmacodynamic analysis of pegloticase in subjects with hyperuricemia and treatment-failure goutJ Clin Pharmacol20084870871818420531
   PubMed Web of Science ®Google Scholar
• Lyseng-WilliamsonKAPegloticase: in treatment-refractory chronic goutDrugs2011712179219222035516
   PubMed Web of Science ®Google Scholar
• GansonNJKellySJScarlettESundyJSHershfieldMSControl of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidaseArthritis Res Ther20068R1216356199
   PubMed Web of Science ®Google Scholar
• HamburgerSALipskyPEKhannaDSimonLSafety and efficacy of long-term pegloticase (KRYSTEXXA_) Pegloticase treatment in adult patients with chronic gout refractory to conventional therapy [abstract no OP0113]12th Annual Congress of the European League Against RheumatismMay 25–28, 2011London
   Google Scholar
• HershfieldMSRobertsLJ2ndGansonNJTreating gout with pegloticase, a PEGylated urate oxidase, provides insight into the importance of uric acid as an antioxidant in vivoProc Natl Acad Sci U S A2010107143511435620660758
   PubMed Web of Science ®Google Scholar
• BarafHSGutierrez-UrenaSVazquez-MelladoJProgressive reduction in tophus burden with pegloticase therapy in patients with chronic gout refractory to conventional therapy [abstract]Arthritis Rheum201062Suppl 1015710.1002/art.27926
   Google Scholar
• RichettePBardinTGoutLancet201037531832819692116
   PubMed Web of Science ®Google Scholar
• TerkeltaubRAClinical practice. GoutN Engl J Med20033491647165514573737
   PubMed Web of Science ®Google Scholar
• EaHKChalesGLioteFPegloticase and chronic goutJAMA20113061979 author reply, 1979–198022068987
   PubMed Web of Science ®Google Scholar
• SampsonHAMunoz-FurlongACampbellRLSecond symposium on the definition and management of anaphylaxis: summary report – Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposiumJ Allergy Clin Immunol200611739139716461139
   PubMedGoogle Scholar
• CollinsRBaigentCSandercockPPetoRAntiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. Antiplatelet Trialists’ CollaborationBMJ1994309121512177987156
   PubMed Web of Science ®Google Scholar
• StevensonWSHylandCDZhangJGDeficiency of 5-hydroxyisourate hydrolase causes hepatomegaly and hepatocellular carcinoma in miceProc Natl Acad Sci U S A2010107166251663020823251
   PubMed Web of Science ®Google Scholar
• JansenTLRichettePPerez-RuizFInternational position paper on febuxostatClin Rheumatol20102983584020401506
   PubMed Web of Science ®Google Scholar
• BeckerMASchumacherHRJrWortmannRLFebuxostat compared with allopurinol in patients with hyperuricemia and goutN Engl J Med20053532450246116339094
   PubMed Web of Science ®Google Scholar
• ReindersMKHaagsmaCJansenTLA randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with goutAnn Rheum Dis20096889289718633127
   PubMed Web of Science ®Google Scholar
• ReindersMKvan RoonENJansenTLEfficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinolAnn Rheum Dis200968515618250112
   PubMed Web of Science ®Google Scholar
• JansenTLReindersMKvan RoonENBrouwersJRBenzbromarone withdrawn from the European market: another case of “absence of evidence is evidence of absence”?Clin Exp Rheumatol20042265115485024
   PubMed Web of Science ®Google Scholar